In this regard, in our study we aimed to devise a model to predict the NSCLC recurrence, purposely neglecting the genomic information provided by the clinical features EGFR and KRAS, that are clinically expansive and time-consuming to obtain. This evidence concerns the gene KRAS and non-small cell lung carcinoma.